Clinical Supply, Clinical Trials and Gene Editing

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Worldwide Clinical Trials

NOVEMBER 12, 2024

For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. Cell therapy, specifically, is changing our narrative around chronic and lethal conditions.

Gene Therapy

Gene Therapy Clinical Supply Trials Gene

Oxford Biomedica and Beam Therapeutics sign CAR-T deal

The Pharma Data

AUGUST 4, 2020

The agreement also puts in place a three year clinical supply agreement for the two companies. Under the terms of the deal, Oxford Biomedica will receive an undisclosed upfront payment, with additional payment related to development and manufacturing of lentiviral vectors for use in clinical trials.

Gene Editing

Gene Editing Licensing Licensing Clinical Supply

Clinical Research Informer

Logistics in Focus: Orchestrating the Challenges of Cell Therapy

Oxford Biomedica and Beam Therapeutics sign CAR-T deal

Webinars

Stay Connected